{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:52:18Z","timestamp":1776729138350,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006734","name":"PRIN","doi-asserted-by":"publisher","award":["2008ZTN724"],"award-info":[{"award-number":["2008ZTN724"]}],"id":[{"id":"10.13039\/100006734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.intimp.2015.06.024","type":"journal-article","created":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T05:33:15Z","timestamp":1435555995000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Mario","family":"Venza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Visalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Agliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Teti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Venza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.06.024_bb0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11912-013-0342-4","article-title":"Sun exposure, sunbeds and sunscreens and melanoma. What are the controversies?","volume":"15","author":"Bataille","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2015.06.024_bb0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138920291506150106145932","article-title":"Epigenetic effects of cadmium in cancer: focus on melanoma","volume":"15","author":"Venza","year":"2014","journal-title":"Curr. Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2015.06.024_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tiv.2014.10.020","article-title":"Epigenetic marks responsible for cadmium-induced melanoma cell overgrowth","volume":"29","author":"Venza","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.intimp.2015.06.024_bb0020","first-page":"89","article-title":"Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune","volume":"1826","author":"van den Hurk","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.intimp.2015.06.024_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbagrm.2014.12.004","article-title":"Epigenetic regulation of p14(ARF) and p16(INK4A) expression in cutaneous and uveal melanoma","volume":"1849","author":"Venza","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.intimp.2015.06.024_bb0030","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1177\/1430.15828","article-title":"Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines","volume":"100","author":"Venza","year":"2014","journal-title":"Tumori"},{"issue":"2","key":"10.1016\/j.intimp.2015.06.024_bb0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/pcmr.12049","article-title":"Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells","volume":"26","author":"Venza","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2015.06.024_bb0040","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2015.06.024_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10495-005-6060-0","article-title":"Death to the bad guys: targeting cancer via Apo2L\/TRAIL","volume":"10","author":"Bouralexis","year":"2005","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2015.06.024_bb0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00109-007-0194-1","article-title":"The promise of TRAIL\u2014potential and risks of a novel anticancer therapy","volume":"85","author":"Koschny","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.intimp.2015.06.024_bb0055","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1158\/1541-7786.MCR-08-0313","article-title":"TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5","volume":"6","author":"Zhang","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.024_bb0060","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbrc.2013.10.114","article-title":"Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma","volume":"441","author":"Venza","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2015.06.024_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10495-010-0535-3","article-title":"Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist","volume":"16","author":"Griffith","year":"2011","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2015.06.024_bb0070","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/030089161109700614","article-title":"Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically","volume":"97","author":"Li","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.intimp.2015.06.024_bb0075","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.1158\/0008-5472.CAN-08-1296","article-title":"Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo","volume":"68","author":"Vogler","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2015.06.024_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/biof.5520340307","article-title":"Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis","volume":"34","author":"Zobalova","year":"2008","journal-title":"BioFactors"},{"issue":"12","key":"10.1016\/j.intimp.2015.06.024_bb0085","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10495-006-0283-6","article-title":"Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells","volume":"11","author":"Gillespie","year":"2006","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.intimp.2015.06.024_bb0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/B:APPT.0000038036.31271.50","article-title":"Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors","volume":"9","author":"Facchetti","year":"2004","journal-title":"Apoptosis"},{"issue":"8","key":"10.1016\/j.intimp.2015.06.024_bb0095","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2015.06.024_bb0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.intimp.2014.05.024","article-title":"Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP","volume":"21","author":"Venza","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"44","key":"10.1016\/j.intimp.2015.06.024_bb0105","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/onc.2011.614","article-title":"Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP","volume":"31","author":"Bangert","year":"2012","journal-title":"Oncogene"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2015.06.024_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-5793(03)01452-2","article-title":"Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors","volume":"557","author":"Holmes","year":"2004","journal-title":"FEBS Lett."},{"issue":"19","key":"10.1016\/j.intimp.2015.06.024_bb0115","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1128\/MCB.24.19.8541-8555.2004","article-title":"Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity","volume":"24","author":"Ricci","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.024_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.leu.2404583","article-title":"Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer","volume":"21","author":"Hu","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.intimp.2015.06.024_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in cancer","volume":"12","author":"Zhang","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2015.06.024_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/156800908783769355","article-title":"Modulation of TRAIL-induced apoptosis by HDAC inhibitors","volume":"8","author":"Fulda","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.intimp.2015.06.024_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2010.04.029","article-title":"HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis","volume":"297","author":"Morales","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2015.06.024_bb0140","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1038\/cddis.2013.481","article-title":"Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer","volume":"4","author":"Riley","year":"2013","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.intimp.2015.06.024_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1368-8375(99)00085-8","article-title":"Oral mucosal melanoma: epidemiology and pathobiology","volume":"36","author":"Hicks","year":"2000","journal-title":"Oral Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2015.06.024_bb0150","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1158\/0008-5472.CAN-07-1310","article-title":"c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.024_bb0155","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semcancer.2006.08.004","article-title":"Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function","volume":"16","author":"Hann","year":"2006","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.024_bb0160","first-page":"909","article-title":"Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models","volume":"35","author":"Bracker","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2015.06.024_bb0165","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1074\/jbc.M112.432377","article-title":"Protein kinase A regulates MYC protein through transcriptional and post-translational mechanisms in a catalytic subunit isoform-specific manner","volume":"288","author":"Padmanabhan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.intimp.2015.06.024_bb0170","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/onc.2010.31","article-title":"Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1","volume":"29","author":"Cobbold","year":"2010","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.intimp.2015.06.024_bb0175","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1158\/0008-5472.CAN-11-3605","article-title":"Activation of Ras\/PI3K\/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells","volume":"72","author":"Tsai","year":"2012","journal-title":"Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2015.06.024_bb0180","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2014the development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.intimp.2015.06.024_bb0185","first-page":"6318","article-title":"Bax is a transcriptional target and mediator of c-myc-induced apoptosis","volume":"60","author":"Mitchell","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2015.06.024_bb0190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1535-6108(04)00113-8","article-title":"Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway","volume":"5","author":"Wang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2015.06.024_bb0195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.emboj.7601551","article-title":"c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis","volume":"26","author":"Nieminen","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2015.06.024_bb0200","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1158\/0008-5472.CAN-08-0850","article-title":"Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation","volume":"68","author":"Kotliarova","year":"2008","journal-title":"Cancer Res."},{"issue":"58","key":"10.1016\/j.intimp.2015.06.024_bb0205","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1038\/sj.onc.1209738","article-title":"Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation","volume":"25","author":"Hama\u00ef","year":"2006","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.intimp.2015.06.024_bb0210","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.cdd.4401416","article-title":"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L\/TRAIL-induced apoptosis","volume":"11","author":"Chawla-Sarkar","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2015.06.024_bb0215","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.1038\/cddis.2014.410","article-title":"Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma","volume":"5","author":"Grazia","year":"2014","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2015.06.024_bb0220","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1074\/jbc.M111.286526","article-title":"Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression","volume":"287","author":"Ding","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2015.06.024_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/nnm.14.101","article-title":"A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy","volume":"10","author":"Pan","year":"2015","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2015.06.024_bb0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.canlet.2014.11.033","article-title":"Ran signaling in melanoma: implications for the development of alternative therapeutic strategies","volume":"357","author":"Caputo","year":"2015","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.intimp.2015.06.024_bb0235","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-08-0657","article-title":"Sp1-mediated TRAIL induction in chemosensitization","volume":"68","author":"Xu","year":"2008","journal-title":"Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2015.06.024_bb0240","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.biocel.2007.03.009","article-title":"HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway","volume":"39","author":"Tsapis","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"11","key":"10.1016\/j.intimp.2015.06.024_bb0245","doi-asserted-by":"crossref","first-page":"e49219","DOI":"10.1371\/journal.pone.0049219","article-title":"Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas","volume":"7","author":"Nesterenko","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2015.06.024_bb0250","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1073\/pnas.0510341103","article-title":"The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases","volume":"103","author":"Simonini","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.intimp.2015.06.024_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00401-006-0082-8","article-title":"Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases","volume":"112","author":"H\u00f6lsken","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2015.06.024_bb0260","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2015.06.024_bb0265","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2015.06.024_bb0270","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2006","journal-title":"Blood"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915300023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915300023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:38:29Z","timestamp":1755650309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915300023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1567576915300023"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.06.024","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}